Loading...
Loading...
NLTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 26.1M |
| Operating I/L | -26.1M |
| Other Income/Expense | 4.1M |
| Interest Income | 2.9M |
| Pretax | -22.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -22.0M |
Neoleukin Therapeutics, Inc. is a biopharmaceutical company specializing in developing immunotherapies for cancer, inflammation, and autoimmunity disorders through protein design technology. Their lead product candidate, NL-201, is a de novo protein designed to replicate the therapeutic activity of cytokines interleukin (IL)-2/IL-15 for treating various cancers, including renal cell carcinoma and melanoma.
